Introduction Colorectal cancer (CRC) screening and surveillance have significantly reduced cancer-related mortality. However, in adults aged ≥75 years, clinical decision-making becomes complex.
Introduction
Colorectal cancer (CRC) screening and surveillance have significantly reduced cancer-related mortality. However, in adults aged ≥75 years, clinical decision-making becomes complex. While cancer risk increases with age, competing risks—particularly non-cancer mortality and frailty—also rise substantially. Current guidelines provide limited clarity on when to stop surveillance colonoscopy, especially in patients with prior adenomas, where the perceived cancer risk often drives continued procedures despite uncertain benefit.
Problem Statement
In older adults ≥75 years, it is unclear whether the risk of colorectal cancer justifies continued surveillance colonoscopy, particularly when competing risks of mortality are high.
Summary
This large Veterans Affairs cohort study of over 90,000 older adults provides important clarity. Over a 10-year follow-up, the risk of CRC remained low—even in those with prior adenomas (1.1% incidence, 0.5% CRC mortality)—and only marginally higher than those without adenomas. In stark contrast, non-CRC mortality approached nearly 50%, far exceeding cancer-related risks across all frailty levels.
Even among high-risk groups (prior adenoma, increasing frailty), the likelihood of dying from non-cancer causes was substantially higher than developing or dying from CRC. These findings highlight that the benefit of continued surveillance colonoscopy diminishes significantly with age and comorbidity burden.
Clinically, this study supports a paradigm shift—from routine surveillance to individualized decision-making. In many older adults, especially those with frailty, it may be more appropriate to deprioritize colonoscopy and focus on overall health, quality of life, and management of comorbid conditions.
Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...
Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...
Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...
Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...
Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...
Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.